BASE mRNA facility focuses on messenger RNA design, manufacturing, and research. They provide end-to-end research services to design, manufacture, and test new mRNA medicines.

BASE mRNA facility

Arrowhead Pharmaceuticals focuses on developing therapies using RNA interference technology to target genes associated with diseases, particularly those with significant unmet medical needs. self-described as aiming to have numerous products in clinical trials or on the market by 2025.

Arrowhead Pharmaceuticals

Aurigene Oncology is a clinical stage biotech company focused on the discovery and development of novel and effective therapeutics for the treatment of cancer. They leverage expertise in oncology to benefit cancer patients worldwide.

Aurigene Oncology

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals develops RNA interference (RNAi) therapeutics aimed at silencing genes that cause or contribute to disease, focusing on various difficult-to-treat diseases, including rare and common conditions.

Metric
Company Name	BASE mRNA facility	Arrowhead Pharmaceuticals	Aurigene Oncology
Symbol
MSH ID	AU:ORG:BASEFACILITY	COM:ARROWHEADPHARMA	COM:AURIGENE
Market	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Biotechnology	Biotechnology
Country	AU	US	IN
Stage		Post-IPO Debt
Employee Count
Website	basefacility.org.au	arrowheadpharma.com	aurigene.com
LinkedIn	base-facility
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic		15.59K
Web Traffic Growth		0.03
Valuation
Raised Capital		400M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:ALNYLAM

Alnylam Pharmaceuticals

Last Close

246.80

22/11 21:00

Market Cap

31.59B

Beta: -

Volume Today

450.15K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue